Introduction
============

COPD is the fourth leading cause of death worldwide and ranks among the primary causes of disability in developed countries.[@b1-copd-13-2131] The GOLD predicts that COPD will rise from the fourth to the third leading cause of death worldwide by 2020.[@b2-copd-13-2131]

COPD is a chronic systemic inflammatory disease, characterized by persistent respiratory symptoms and chronic airflow limitation. Inflammation is the most important factor in COPD pathogenesis. The most common causes of mortality in patients with COPD, respiratory insufficiency and cardiovascular complications, are attributed to systemic inflammation.[@b3-copd-13-2131] Systemic inflammation can be assessed on the basis of inflammatory markers such as CRP, ILs, TNF-α and COX-2.[@b4-copd-13-2131] Previous studies have demonstrated that these inflammatory molecules are involved in the pathogenesis of COPD. For example, IL-1β is a key factor in immune response,[@b5-copd-13-2131] IL-8 is involved in inflammatory cell recruitment[@b6-copd-13-2131]--[@b9-copd-13-2131] and COX-2 expression is associated with recruitment of T cells, macrophages and neutrophils to the lung.[@b10-copd-13-2131]

The systemic inflammatory process in COPD involves both innate and adaptive immunity.[@b11-copd-13-2131] NF-κB family genes regulate genes required for both the innate and adaptive immune responses.[@b12-copd-13-2131],[@b13-copd-13-2131] Activation of the NF-κB family plays a central role in regulating the process of inflammation. NF-κB signaling can be activated by inflammatory molecules; conversely, activated NF-κB signaling can stimulate the secretion of more inflammatory molecules. When the NF-κB signaling pathway is blocked, the expression of TNF-α and IL-6 is downregulated.[@b14-copd-13-2131],[@b15-copd-13-2131]

NF-κB signaling is well known to play essential roles in inflammatory responses. However, whether the expression levels of NF-κB family genes affect inflammatory responses is unclear. Furthermore, little is known regarding the association of NF-κB family genes expression levels with the pathogenesis of COPD.

In this study, to explore the relationship among the mRNA expression of NF-κB family genes, levels of inflammatory molecules and COPD pathogenesis, we detected the mRNA levels of NF-κB family genes (*NF-κB1*, *NF-κB2* and *c-REL*) and the levels of serum inflammatory molecules (COX-2, CRP, IL-1β, IL-6, IL-8, IL-12 and TNF-α) in COPD patients and healthy controls.

Methods
=======

Subjects
--------

A total of 186 unrelated patients with acute exacerbation of COPD were recruited from The First Hospital of Jilin University between 2013 and 2014. COPD was defined on the basis of the diagnostic standards for COPD from the American Thoracic Society with post-bronchodilator FEV~1~/FVC \<70%. Patients with complications of other diseases were excluded. The disease severity was assessed to stratify patients on the basis of moderate, severe and very severe lung function according to the recommended criteria from GOLD. Control subjects (n = 180), residing in the same geographical area as the COPD group, were randomly selected during their routine checkups as part of their annual body examinations. They were classified as healthy controls on the basis of the results of physical examination coupled with the absence of any reasons to suspect COPD.

Every subject provided a written informed consent and was well informed of the study protocol. The study was approved by the ethics committee of the School of Public Health, Jilin University, Changchun, China. Peripheral venous fasting blood was collected in two tubes, one containing disodium-EDTA as an anticoagulant, from which extraction was performed immediately, and the other containing no anticoagulant, from which the blood was used for separation of serum.

mRNA levels of NF-κB family genes (*NF-κB1*, *NF-κB2* and *c-REL*)
------------------------------------------------------------------

Total RNA was extracted from the peripheral blood of each subject using trizol reagent (Takara Biomedical Technology, Beijing, China) according to the manufacturer's protocol. Total RNA quantity was measured with an ultraviolet spectrophotometer (BioPhotometer plus; Eppendorf AG, Hamburg, Germany). RNA integrity was assessed through electrophoresis on an agarose gel. First-strand cDNA synthesis was carried out on 500 ng of total RNA, using a Superscript II first-strand synthesis kit for reverse transcription PCR (Takara Biomedical Technology), according to the manufacturer's protocol. Finally, 2 μL of cDNA was used for real-time quantitative PCR.

Levels of mRNAs of NF-κB family genes (*NF-κB1*, *NF-κB2* and *c-REL*) were measured in samples using a real-time quantitative PCR kit (Takara Biomedical Technology), according to the manufacturer's protocol. The samples were prepared in a volume of 25 μL, containing 2 μL cDNA, 12.5 μL SYBR Premix Ex Taq™ (2×), 0.5 μL PCR reverse primer (10 μM), 0.5 μL PCR forward primer (10 μM), 0.5 μL ROX Reference Dye II (50×) and 9 μL dH~2~O. Then, the mixture was denatured at 95°C for 5 minutes, and subjected to 40 cycles at 95°C (5 seconds) and 60°C (35 seconds) before a final incubation at 95°C (15 seconds). Finally, all primers were designed to have an annealing temperature of 60°C. The primers are shown in [Table 1](#t1-copd-13-2131){ref-type="table"}.

All samples were run in triplicate. Wells without template, but with pure water, were included as negative controls. *NF-κB1*, *NF-κB2* and *c-REL* mRNA expression levels were quantified via the 2^−ΔCT^ method.

Serum inflammatory cytokine levels
----------------------------------

Blood samples were separated by centrifugation at 3,500 rpm for 10 minutes. Serum samples were stored at −80°C until testing. COX-2, CRP, IL-1β, IL-6, IL-8, IL-12 and TNF-α serum levels were measured using the commercially available enzyme-linked immunosorbent assay kits (R&D Systems, Inc., Minneapolis, MN, USA), according to the manufacturer's instructions.

Statistical analysis
--------------------

Statistical analysis was carried out using the SPSS 16.0 software. The results of the normal distribution test showed that all continuous variables were normally distributed. Hence, data are expressed as mean ± standard deviation. Data were compared with Student's *t*-test or analysis of variance for continuous variables and chi-square test for categorical variables (sex and smoking). Logistic regression models were used to adjust for smoking and to calculate the ORs and 95% CIs. A two-sided *P*-value \<0.05 was considered statistically significant.

Results
=======

Characteristics of study subjects
---------------------------------

[Table 2](#t2-copd-13-2131){ref-type="table"} lists the demographic and clinical characteristics of the 186 patients with COPD of varying severity and 180 control subjects. There was no statistically significant difference between the COPD group and the control group with respect to the frequency distribution of age, and the sex distribution was unbiased (all *P* \> 0.05). Compared to the control group, the COPD group had more smokers. With increase in disease severity, the number of male patients and smoking patients was significantly higher.

mRNA levels of NF-κB family genes
---------------------------------

The relative mRNA levels of the NF-κB family genes were significantly higher in the COPD group than in the control group ([Figure 1](#f1-copd-13-2131){ref-type="fig"}). To explore the relationship between the mRNA levels of NF-κB family genes and disease severity, the relative mRNA levels of NF-κB family genes among patients with different severities of COPD were further analyzed. However, there were no significant differences among patients with different severities of COPD ([Figure 2](#f2-copd-13-2131){ref-type="fig"}).

Levels of serum inflammatory molecules
--------------------------------------

There was a statistically significant difference between the COPD group and the control group with respect to the levels of serum inflammatory molecules (*P* \< 0.001) ([Table 3](#t3-copd-13-2131){ref-type="table"}). The levels of all the measured inflammatory molecules were significantly higher in the COPD group than in the control group. After adjustment for smoking, the OR and 95% CI for COX-2, CRP, IL-1β, IL-6, IL-8, IL-12 and TNF-α were 1.328 (1.249--1.411), 6.088 (4.162--8.904), 2.334 (1.845--2.951), 1.818 (1.590--2.079), 1.221 (1.169--1.274), 1.495 (1.372--1.628) and 1.530 (1.388--1.687), respectively.

Then, patients and controls were divided into smoker and nonsmoker groups to analyze the differences in levels of inflammatory molecules. The levels of inflammatory molecules were significantly higher in smoker and nonsmoker patients than in healthy smokers and nonsmokers ([Table 4](#t4-copd-13-2131){ref-type="table"}).

To explore the relationship between the levels of serum inflammatory molecules and disease severity, the levels of inflammatory molecules among patients with different severities of COPD were further analyzed. However, there were no significant differences among patients with different severities of COPD ([Table 5](#t5-copd-13-2131){ref-type="table"}).

Relationship between expression of NF-κB family genes and inflammatory molecules
--------------------------------------------------------------------------------

To determine the relationship between the expression of NF-κB family genes and inflammatory molecules, we conducted a subgroup analysis based on the NF-κB expression level. If a patient's mRNA level was higher than the average level of the controls, we placed the patient in an over-expression subgroup; otherwise, the patient was placed in an under-expression subgroup. As shown in [Figure 3](#f3-copd-13-2131){ref-type="fig"}, the levels of IL-1β, IL-8 and COX-2 were significantly different between the *NF-κB2* over-expression and under-expression subgroups (*P* \< 0.05). The IL-1β, IL-8 and COX-2 levels were significantly lower in the *NF-κB2* under-expression subgroup than in the *NF-κB2* over-expression subgroup. The COX-2 levels were significantly different between the *c-REL* over-expression subgroup and the *c-REL* under-expression subgroup (*P* \< 0.05). Compared to the *c-REL* over-expression subgroup, the COX-2 level was significantly lower in the *c-REL* under-expression subgroup.

Discussion
==========

The inflammatory response differs in different phases of the disease in COPD patients. Therefore, we ensured that the COPD patients we recruited were in the acute exacerbation phase.

Previous studies have suggested that smoking is an independent risk factor for COPD. In this case--control study, we matched COPD group and control group by age and sex. Smoking history was investigated as well. Compared with the control group, the COPD group contained more smokers. With increasing severity of the disease, the number of male patients and smoking patients significantly increased. Our results confirmed that smoking is associated with COPD as well as with severity.

The main pathological features of COPD are systemic inflammation in the airways, pulmonary parenchyma and vessels, as mediated by inflammatory molecules.[@b16-copd-13-2131]--[@b19-copd-13-2131] The most important inflammatory molecules, COX-2, CRP, IL-1β, IL-6, IL-8, IL-12 and TNF-α, are elevated in the serum in COPD patients and are correlated with the disease onset, disease progression, disease severity, etc.[@b20-copd-13-2131]--[@b22-copd-13-2131]

The NF-κB pathway is one of the most important cellular signal transduction pathways involved in the immune function and controlling inflammation. The expression levels of inflammatory molecules are regulated by the NF-κB signaling pathway. Inhibition of the NF-κB signaling pathway may be a potent strategy for the treatment of human inflammatory diseases.[@b23-copd-13-2131],[@b24-copd-13-2131]

In this study, we found that the levels of inflammatory cytokines, including COX-2, CRP, IL-1β, IL-6, IL-8, IL-12 and TNF-α, and the mRNA levels of NF-κB family genes were significantly higher in patients with COPD than in controls. Because systemic inflammation in COPD can be influenced by smoking, we adjusted for smoking with a regression model and divided both patients and controls into smoker and nonsmoker groups to investigate the reason for this association. The results showed that after adjustment for smoking, the levels of all assayed inflammatory molecules remained significantly higher in the COPD group. Moreover, the levels of inflammatory molecules were significantly higher in smoker and nonsmoker patients than in healthy smokers and nonsmokers. These results indicated that the elevated levels of inflammatory cytokines and mRNA levels of NF-κB family genes are major factors in COPD.

To explore the relationship among the mRNA levels of NF-κB family genes, levels of serum inflammatory molecules and disease severity, the relative mRNA levels of NF-κB family genes and the levels of serum inflammatory molecules in patients with varying COPD severity were further analyzed. However, we did not find any significant differences among patients with different severities of COPD. This result may have occurred because the COPD subjects were in acute exacerbation phases. Patients with acute exacerbation of COPD are characterized by a worsening of the respiratory symptoms, dyspnea and cough and/or sputum exceeding the usual day-to-day variations. When patients were in the acute exacerbation phases, the NF-κB signaling pathway in the lung was activated, and inflammation was markedly increased. In addition, this process was not associated with lung function and disease severity. These results led us to hypothesize that the mRNA expression of NF-κB family genes might be related to the expression of inflammatory molecules, and might influence the progression of COPD. To assess the relationships among the expression of NF-κB family genes and inflammatory molecules, we conducted a subgroup analysis based on the NF-κB expression level. The results showed that compared with *NF-κB2* over-expression subgroup, the IL-1β, IL-8 and COX-2 levels were significantly lower in *NF-κB2* under-expression subgroup; compared with *c-REL* over-expression subgroup, the COX-2 level was significantly lower in *c-REL* under-expression subgroup. These results suggested that *NF-κB2* over-expression correlated with IL-1β, IL-8 and COX-2, and *c-REL* over-expression correlated with COX-2.

NF-κB regulates various genes involved in immune response, inflammation, cell survival and development.[@b25-copd-13-2131] Elevated mRNA levels of NF-κB family genes may promote the onset and progression of COPD. *NF-κB2* is synthesized as a large precursor of the 100-kDa protein (p100) precursor, which is processed by the proteasome to generate p52, corresponding to the amino-terminal half of p100. A study with p52 transgenic mice has suggested a causal role for sustained *NF-κB2* activation in the development of inflammation and autoimmunity.[@b26-copd-13-2131] Our study demonstrated that over-expression of *NF-κB2* is associated with the levels of IL-1β, IL-8 and COX-2, and over-expression of *c-REL* is associated with the level of COX-2. The results indicated a potential relationship between the NF-κB family genes and the inflammation involved in COPD, and implied that over-expression of *NF-κB2* and *c-REL* may be involved in the pathogenesis of COPD.

Conclusion
==========

In conclusion, we confirmed that the expression of NF-κB family genes and inflammatory cytokines was significantly higher in patients with COPD than in controls. Over-expression of *NF-κB2* was associated with IL-1β, IL-8 and COX-2 levels, whereas over-expression of *c-REL* was associated with COX-2 level. Over-expression of both *NF-κB2* and *c-REL* was related to COPD.
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![Relative mRNA levels of NF-κB family genes in COPD group and control group. Relative mRNA levels of NF-κB family genes were expressed as the mean value ± standard deviation. \**P* \< 0.05, compared with the control group.\
**Abbreviations:** NF-κB, nuclear factor-κB; COPD, chronic obstructive pulmonary disease.](copd-13-2131Fig1){#f1-copd-13-2131}

![Relative mRNA levels of NF-κB family genes among patients with different severities of COPD. Relative mRNA levels of NF-κB family genes were expressed as the mean value ± standard deviation.\
**Abbreviations:** NF-κB, nuclear factor-κB; COPD, chronic obstructive pulmonary disease.](copd-13-2131Fig2){#f2-copd-13-2131}

![Subgroup analysis of inflammatory molecules levels based on the mRNA expression levels of NF-κB family genes in patients with COPD: (**A**) IL-1β, (**B**) IL-6, (**C**) IL-8, (**D**) IL-12, (**E**) TNF-α, (**F**) COX-2 and (**G**) CRP. \**P* \< 0.05, compared with over-expression subgroup.\
**Abbreviations:** NF-κB, nuclear factor-κB; COPD, chronic obstructive pulmonary disease; IL, interleukin; TNF-α, tumor necrosis factor-α; COX-2, cyclooxygenase-2; CRP, C-reactive protein.](copd-13-2131Fig3){#f3-copd-13-2131}

###### 

Primer sequences of candidate genes

  Gene name   Primer                          Sequence
  ----------- ------------------------------- ------------------------------
  *β-actin*   Forward                         5′-CTGGAACGGTGAAGGTGACA-3′
  Reverse     5′-CGGCCACATTGTGAACTTTG-3′      
  *NF-κB1*    Forward                         5′-CACAAGGCAGCAAATAGACGAG-3′
  Reverse     5′-TGGGGCATTTTGTTGAGAGTT-3′     
  *NF-κB2*    Forward                         5′-GGCTGGTGCTGACATCCAT-3′
  Reverse     5′-CTGCTTCGGGTGTCCTTCTC-3′      
  *c-REL*     Forward                         5′-GACGACTGCTCTTCCTCCTGTT-3′
  Reverse     5′-TCATCTCCTCCTCTGACACTTCC-3′   

###### 

Baseline characteristics of the COPD group and control group

               COPD group (n = 186)   Control group (n = 180) (%)   *t*/*χ*^2^      *P*-value                                
  ------------ ---------------------- ----------------------------- --------------- --------------- --------------- -------- ---------
  Age          62.21 ± 13.22          63.25 ± 10.92                 59.43 ± 9.62    63.17 ± 11.54   63.03 ± 11.53   0.115    0.909
  Sex                                                                                                                        
   Male        24 (45.3)              30 (50.0)                     43 (58.9)       97 (52.2%)      77 (42.8)       3.222    0.073
   Female      29 (54.7)              30 (50.0)                     30 (41.1)       89 (47.8%)      103 (57.2)               
  Smoking                                                                                                                    
   No          35 (66.0)              36 (60.0)                     35 (47.9)       106 (53.0%)     135 (75.0)      13.195   \<0.001
   Yes         18 (34.0)              24 (40.0)                     38 (52.1)       80 (47.0%)      45 (25.0)                
  Pack years   45.00 ± 44.75          40.00 ± 27.50                 20.00 ± 30.00                                            

**Notes:** Age and pack years are expressed as mean ± standard error of the mean. The difference in age between the COPD group and the control group was compared with Student's *t*-test. Sex and smoking are expressed as n (%). The differences were compared with Pearson's chi-square test.

**Abbreviation:** COPD, chronic obstructive pulmonary disease.

###### 

Differences in inflammatory molecules levels between COPD group and control group (mean ± standard deviation)

  Inflammatory molecules   COPD group (n = 186)   Control group (n = 180)   *t*      *P*-value   SD (95% CI)[a](#tfn3-copd-13-2131){ref-type="table-fn"}
  ------------------------ ---------------------- ------------------------- -------- ----------- ---------------------------------------------------------
  COX-2 (U/L)              71.60 ± 9.40           50.64 ± 0.09              21.508   \<0.001     1.328 (1.249--1.411)
  CRP (mg/L)               6.20 ± 1.21            4.15 ± 1.03               17.256   \<0.001     6.088 (4.162--0.904)
  IL-1β (pg/mL)            43.33 ± 5.70           28.60 ± 5.07              25.894   \<0.001     2.334 (1.845--2.951)
  IL-6 (pg/mL)             29.90 ± 5.32           20.57 ± 3.37              19.858   \<0.010     1.818 (1.590--2.079)
  IL-8 (pg/mL)             76.28 ± 13.29          49.99 ± 10.71             20.661   \<0.001     1.221 (1.169--1.274)
  IL-12 (pg/mL)            30.42 ± 5.72           21.74 ± 4.05              16.609   \<0.001     1.495 (1.372--1.628)
  TNF-α (pg/mL)            45.35 ± 8.25           29.24 ± 4.25              23.287   \<0.001     1.530 (1.388--1.687)

**Note:**

Compared with controls after adjustment for smoking.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; SD, standard deviation; CI, confidence interval; COX-2, cyclooxygenase-2; CRP, C-reactive protein; IL, interleukin; TNF-α, tumor necrosis factor-α.

###### 

Differences in inflammatory molecules levels between smokers and nonsmokers with or without COPD

  Inflammatory molecules   Control group   COPD group      *F*                  *P*-value                      
  ------------------------ --------------- --------------- -------------------- -------------------- --------- ---------
  COX-2 (U/L)              51.09 ± 8.74    49.30 ± 10.06   71.20 ± 9.56^a,b^    72.14 ± 9.21^a,b^    154.662   \<0.001
  CRP (mg/L)               4.13 ± 1.05     4.21 ± 0.96     6.09 ± 1.16^a,b^     6.34 ± 1.26^a,b^     100.269   \<0.001
  IL-1β (pg/mL)            28.48 ± 5.05    28.97 ± 5.17    42.90 ± 5.53^a,b^    43.90 ± 5.91^a,b^    223.974   \<0.001
  IL-6 (pg/mL)             20.55 ± 3.37    20.63 ± 3.44    29.51 ± 4.97^a,b^    30.42 ± 5.75^a,b^    131.998   \<0.010
  IL-8 (pg/mL)             49.90 ± 10.73   50.28 ± 10.76   77.75 ± 13.10^a,b^   74.31 ± 13.37^a,b^   144.158   \<0.001
  IL-12 (pg/mL)            21.82 ± 3.94    21.51 ± 4.41    29.75 ± 5.24^a,b^    31.31 ± 6.23^a,b^    94.101    \<0.001
  TNF-α (pg/mL)            29.19 ± 4.23    29.38 ± 4.35    44.68 ± 7.81^a,b^    46.23 ± 8.78^a,b^    181.852   \<0.001

**Notes:**

*P* \< 0.05, compared with nonsmoker controls.

*P* \< 0.05, compared with smoker controls.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; COX-2, cyclooxygenase-2; CRP, C-reactive protein; IL, interleukin; TNF-α, tumor necrosis factor-α.

###### 

Differences in inflammatory molecules levels among patients with different severities of COPD

  Inflammatory molecules   Different severities of COPD   *F*             *P*-value               
  ------------------------ ------------------------------ --------------- --------------- ------- -------
  COX-2 (U/L)              70.98 ± 10.13                  71.49 ± 9.41    72.64 ± 8.75    0.374   0.689
  CRP (mg/L)               6.07 ± 1.16                    6.36 ± 0.94     6.22 ± 1.44     0.583   0.560
  IL-1β (pg/mL)            43.89 ± 5.45                   42.61 ± 5.63    43.33 ± 5.44    0.537   0.586
  IL-6 (pg/mL)             28.48 ± 4.90                   30.53 ± 4.97    30.53 ± 6.46    1.753   0.177
  IL-8 (pg/mL)             74.77 ± 13.79                  76.90 ± 12.91   74.97 ± 12.86   0.336   0.715
  IL-12 (pg/mL)            28.76 ± 5.03                   30.85 ± 5.27    31.03 ± 6.95    1.768   0.175
  TNF-α (pg/mL)            43.78 ± 8.00                   46.97 ± 7.46    45.65 ± 9.70    1.350   0.263

**Abbreviations:** COPD, chronic obstructive pulmonary disease; COX-2, cyclooxygenase-2; CRP, C-reactive protein; IL, interleukin; TNF-α, tumor necrosis factor-α.
